These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 28235977)
1. Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD. D'Urzo A; Singh D; Garcia Gil E NPJ Prim Care Respir Med; 2017 Feb; 27(1):13. PubMed ID: 28235977 [TBL] [Abstract][Full Text] [Related]
2. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610 [TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938 [TBL] [Abstract][Full Text] [Related]
7. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Kew KM; Dias S; Cates CJ Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923 [TBL] [Abstract][Full Text] [Related]
10. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Singh D; Rabe KF; Martinez FJ; Krüll M; Jenkins M; Patel M; Dorinsky P Respir Med; 2022 Jun; 197():106857. PubMed ID: 35512458 [TBL] [Abstract][Full Text] [Related]
11. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428 [TBL] [Abstract][Full Text] [Related]
12. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review. Solidoro P; Patrucco F; Bagnasco D Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714 [No Abstract] [Full Text] [Related]
13. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers. Feldman WB; Avorn J; Kesselheim AS; Gagne JJ JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE Drugs; 2009; 69(5):549-65. PubMed ID: 19368417 [TBL] [Abstract][Full Text] [Related]
17. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Nannini L; Cates CJ; Lasserson TJ; Poole P Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS. Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869 [TBL] [Abstract][Full Text] [Related]
19. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids. van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340 [TBL] [Abstract][Full Text] [Related]
20. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]